$MNKD

4 stories mentioning MNKDUpdated just now

Every FINWIRES story that references MNKD, newest first.

MannKind's Furoscix Auto-Injector Approval, Launch Could Provide Strong Upside to 2026 Revenue Expectation, Wedbush Says

MannKind (MNKD) is expected to get FDA approval for the Furoscix ReadyFlow auto injector by July 26 and launch it in August, providing significant upside to its full-year 2026 revenue expectation, Wedbush Securities said in a research note Friday.Management reiterated its 2026 ReadyFlow net revenue guidance of $110 million to $120 million, assuming about 14% of annual dispenses are generated in Q1 and without any significant contribution from ReadyFlow, the firm noted. Given that assumption, the auto-injector approval could provide strong revenue upside and diversify commercial portfolio, the note added.Wedbush expects Furoscix revenue growth to resume in Q2, projecting revenue of $22.5 million versus consensus of $24.7 million. With ReadyFlow's contribution, the brokerage expects revenue growth to further accelerate in the second half.The company's research suggests approximately 65% of healthcare providers expect to increase the use of Furoscix upon ReadyFlow's approval, the brokerage noted.Wedbush kept an outperform rating on MannKind with a price target of $8 per share.Price: $4.05, Change: $+0.16, Percent Change: +4.11%

$MNKD

Sectors3h ago

Sector Update: Healthcare Stocks Flat to Higher Premarket Friday

Healthcare stocks were flat to higher premarket Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.3%.Tenet Healthcare (THC) shares were up more than 17% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.MannKind's (MNKD) Furoscix ReadyFlow injection has been approved by the US Food and Drug Administration for the treatment of edema, or fluid overload, in adults with heart failure or chronic kidney disease, the company said. MannKind shares were up more than 2% pre-bell.Sanofi (SNY) stock was down more than 1% after the company said it stopped clinical testing and global regulatory applications for its amlitelimab medication for moderate-to-severe atopic dermatitis.

$IBB$MNKD$SNY$THC$XLV

Wire5h ago

MannKind Agrees to $50 Million Private Stock Sale

MannKind (MNKD) said Friday it agreed to a $50 million private placement with institutional investors led by Frazier Life Sciences.The firm is selling about 10.4 million common shares for $3.89 each and pre-funded warrants to buy up to roughly 2.4 million shares at $3.88 per warrant, the company said.The transaction is expected to close on or about Friday, and the business plans to use the net proceeds for general corporate purposes, including a $45 million contingent value rights payment related to the recent US Food and Drug Administration approval of Furoscix ReadyFlow, MannKind said.Shares of the company were up 6.4% in Friday premarket trading.

$MNKD

Wire55d ago

MannKind Says FDA Approves Afrezza for Children, Adolescents With Diabetes

MannKind (MNKD) said Friday the US Food and Drug Administration approved Afrezza, its inhaled mealtime insulin, for use in children and adolescents aged six and older with type 1 or type 2 diabetes.The approval expands Afrezza's label beyond adults and was supported by results from the phase 3 INHALE-1 study and additional long-term safety and efficacy data, the company said.MannKind said eligible patients can access Afrezza for $35 or less per month through its patient support program.Price: $3.80, Change: $+0.16, Percent Change: +4.40%

$MNKD

Track with the FINWIRES app suite

FolioX

Track MNKD in your portfolio

WheelAI

Analyze MNKD options with the wheel strategy

StockInsider

See market sentiment on MNKD